1: Brown, JS, Marcy, SA. The use of botanicals for health purposes by members of a prepaid health plan. Res. Nurs. Health 1991; 14: 339–50.
2: Moore, J, Phipps, K, Marcer, D, Lewith, G.Why do people seek treatment by alternative medicine?. Br. Med. J. 1985; 290: 28–9.
3: Winslow, LC, Kroll, DJ. Herbs as medicine. Arch. Intern. Med. 1998; 158: 2192–9.
4: Schuppan, D, Jia, JD, Brinkhaus, B, Hahn, EG. Herbal products for liver disease: a therapeutic challenge for the new millennium. Hepatology 1999; 30: 1099–104.
5: Trevelyan, J.Herbal medicine. Nurs. Times 1993; 89: 36–8.
6: Schiano, T. Liver injury from herbs and other botanicals. In: Gitlin, N, ed. Clinics in Liver Disease, vol. 2. Chicago: W.B. Saunders, 1998: 607–30.
7: Smith, LW, Culvenor, CCJ. Plant sources of hepatotoxic pyrrolizidine alkaloids. J. Nat. Prod. 1981; 44: 129–52.
8: Wilmot, FC, Robertson, GW. Senecio disease or cirrhosis of the liver due to senecio poisoning. Lancet 1920; II, 828–828.
9: Selzer, G, Parker, RGF. Senecio poisoning exhibiting as Chiari's syndrome. Am. J. Pathol. 1951; 27: 885–907.
10: Bras, G, Jeliffe, DB, Stuart, KL. Veno-occlusive disease of the liver with non-portal type of cirrhosis, occurring in Jamaica. AMA Arch. Pathol. 1954; 57: 285–300.
11: Mohabat, O, Srivastava, RN, Younos, MS, Gholam Gsediq, GG, Merzad, AA, Aram, GN. An outbreak of hepatic veno-occlusive disease in north-western Afghanistan. Lancet 1976; 2: 269–71.
12: Tandon, BN, Tandon, RK, Tandon, HD, Narndranathan, M.An epidemic of veno-occlusive disease of liver in central India. Lancet 1976; 2: 271–2.
13: Stillman, AS, Huxtable, RJ, Consroe, P, Kohnen, P, Smith, S.Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona. Gastroenterology 1977; 73: 349–52.
14: Fox, DW, Hart, MC, Bergeson, PS, Jarrett, PB, Stillman, AE, Huxtable, RJ. Pyrrolizidine (Senecio) intoxication mimicking Reye's syndrome. J. Paediatr. 1978; 93: 980–2.
15: Ridker, PM, Ohkuma, S, McDermott, WV, Trey, C, Huxtable, RJ. Hepatic venoocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985; 88: 1050–4.
16: Weston, CFM, Cooper, BT, Davies, JD. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br. Med. J. 1987; 295: 183.
17: Bach, N, Thung, SN, Schaffner, F.Comfrey herb tea-induced hepatic veno-occlusive disease. Am. J. Med. 1989; 87: 97–9.
18: Prakash, AS, Pereira, TN, Reilly, PE, Seawright, AA. Pyrrolizidine alkaloids in human diet. Mutat. Res. 1999; 15 (443): 53–67.
19: Comfrey In: The Lawrence Review of Natural Products Monograph System. Pharmaceutical Information Associates, 1987;.
20: Roitman, JN. Comfrey and liver damage. Lancet 1981; 1: 944.
21: Huxtable, RJ, Lüthy, J, Zweifel, U.Toxicity of comfrey-pepsin preparations. N. Engl. J. Med. 1986; 315: 1095.
22: Ahmad, VU, Noorwala, M, Mohammad, FV, Sener, B.A new triterpene glycoside from the roots of Symphytum officinale. J. Nat. Prod. 1993; 56: 329–34.
23: Ahmad, VU, Noorwala, M, Mohammad, FV, Sener, B, Gilani, AH, Aftab, K.Symphytoxide A, a triterpenoid saponin from the roots of Symphytum officinale. Phytochemistry 1993; 32: 1003–6.
24: Stegelmeier, BL, Edgar, JA, Colegate, SM, Gardner, DR, Schoch, TK, Coulombe, RA et al. Pyrrolizidine alkaloid plants, metabolism and toxicity. J. Nat. Toxins 1999; 8: 95–116.
25: Betz, JM, Eppley, RM, Taylor, WC, Andrzejewski, D.Determination of pyrrolizidine alkaloids in commercial comfrey products (Symphytum sp.). J. Pharm. Sci. 1994; 83: 649–53.
26: Mattocks, AR. Toxic pyrrolizidine alkaloids in comfrey. Lancet 1980; 2: 1136.
27: Nebert, DW, Nelson, DR, Coon, MJ, Estabrook, RW, Feyereisen, R, Fuji-Kuriyama, Y et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991; 10: 1–14.
28: Huxtable, RJ. New aspects of the toxicology and pharmacology of pyrrolizidine alkaloids. Gen. Pharmacol. 1979; 10: 159–67.
29: Couet, CE, Hopley, J, Hanley, AB. Metabolic activation of pyrrolizidine alkaloids by human, rat and avocado microsomes. Toxicon 1996; 34: 1058–61.
30: Mattocks, AR. Chemistry and Toxicology of Pyrrolizidine Alkaloids, London: Academic Press, 1986: 1.
31: McLean, EK. Senecio and other plants as liver poisons. Isr. J. Med. Sci. 1974; 10: 436–40.
32: Mattocks, AR. Spectrophotometric determination of pyrrolizidine alkaloids – some improvements. Anal. Chem. 1968; 40: 1749–50.
33: Brauchli, J, Lüthy, J, Zweifel, U, Schlatter, C.Pyrrolizidine alkaloids from Symphytum officinale L. and their percutaneous absorbtion in rats. Experientia 1982; 38: 1085–7.
34: Couet, CE, Crews, C, Hanley, AB. Analysis, separation, and bioassay of pyrrolizidine alkaloids from comfrey (Symphytum officinale). Nat. Toxins 1996; 4: 163–7.
35: Lin, G, Zhou, KY, Zhao, XG, Wang, ZT, But, PP. Determination of hepatotoxic pyrrolizidine alkaloids by on-line high performance liquid chromatography mass spectrometry with an electrospray interphase. Rapid Commun. Mass Spectrom. 1998; 12: 1445–56.
36: Roulet, M, Laurini, R, Rivier, L, Calame, A.Hepatic veno-occlusive disease in a newborn infant of a woman drinking herbal tea. J. Pediatr. 1988; 2: 481–500.
37: Sperl, W, Stuppner, H, Gassner, J, Judmaier, W, Dietze, O, Vogel, W.Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea. Eur. J. Pediatr. 1995; 154: 112–16.
38: Essell, JH, Thomson, JM, Harman, GS, Halvorson, RD, Snyder, MJ, Johnson, RA et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for Graft-Versus-Host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784–8.
39: Fried, MW, Connaghan, DG, Sharma, S, Martin, LG, Devine, S, Holland, K et al. Tranjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24: 588–91.
40: Alpert, LI. Veno-occlusive disease of the liver associated with oral contraceptives: case report and review of the literature. Hum. Pathol. 1976; 7: 709–-18.
41: Pappas, SC, Malone, DG, Rabin, L, Hoofnagel, YH, Jones, EA. Hepatic veno-occlusive disease in a patient with systemic lupus erythematosus. Arthritis Rheum. 1984; 27: 104–8.
42: Goodman, ZD, Ishak, KG. Occlusive venous lesions in alcoholic liver disease. Gastroenterology 1982; 83: 786–96.
43: Rollins, BJ. Hepatic veno-occlusive disease. Am. J. Med. 1990; 81: 297–306.
44: Shulman, HM, Fisher, LB, Schoch, HG, Henne, KW, McDonald, GB. Venooclusive disease of the liver after marrow transplantation: histological correlates of clinical sign and symptoms. Hepatology 1994; 19: 1171–80.
45: Sherlock, S.Noncirrhotic extrahepatic and intrahepatic portal hypertension. Semin. Liver Dis. 1982; 2: 202–10.
46: Yeong, ML, Wakefield, St J, Ford, HC. Hepatocyte membrane injury and bleb formation following low dose comfrey toxicity in rats. Int. J. Exp. Pathol. 1993; 74: 211–17.
47: Brooks, SEH, Miller, CG, McKenzie, K, Audretsch, JJ, Bras, G.Acute veno-occlusive disease of the liver. Arch. Pathol. 1970; 89: 507–20.
48: Franke, H.Substructural alterations of liver parenchymal cells induced by xenobiotics. Exp. Pathol. 1990; 39: 139–55.
49: Jewell, S, Bellomo, G, Thor, H, Orrenius, S.Bleb formation in hepatocytes during drug metabolism is caused by disturbances in thiol and calcium ion homeostasis. Science 1982; 217: 1257–8.
50: Miskelly, FG, Goodyer, LI. Hepatic and pulmonary complications of herbal medicines. Postgrad. Med. J. 1992; 68: 935–6.
51: Shubat, PJ, Banner, W, Huxtable, RJ. Pulmonary vascular response induced by the pyrrolizidine alkaloid monocrotaline in rats. Toxicon 1987; 25: 995–1002.
52: Guzowski, DE, Solgado, ED. Changes in main pulmonary artery of rats with monocrotaline induced pulmonary hypertension. Arch. Pathol. Lab. Med. 1987; 111: 741–5.
53: Hirono, I, Haga, M, Fujii, M, Mori, H.Induction of hepatic tumors in rats by senkirkine and symphytine. J. Natl. Cancer Inst. 1979; 63: 469–72.
54: Petry, TW, Bowden, GT, Huxtable, RJ, Sipes, IG. Characterization of hepatic DNA damage induced in rats by the pyrrolizidine alkaloid monocrotaline. Cancer Res. 1984; 44: 1505–9.
55: Behninger, C, Abel, G, Roder, E, Neuberger, V, Goggelmann, W.Studies on the effect of an alkaloid extract of Symphytum officinale on human lymphocyte cultures. Planta Med. 1989; 55: 518–22.
56: Olinescu, A, Manda, G, Neagu, M, Hristescu, M, Dasanu, C.Action of some proteic and carbohydrate components of Symphytum officinale upon normal and neoplastic cells. Roum. Arch. Microbiol. Immunol. 1993; 52: 73–80.
57: Culvenor, CC. Estimated intakes of pyrrolizidine alkaloids by humans. A comparison with dose rates causing tumors in rats. J. Toxicol. Environ. Health 1983; 11: 625–35.
58: Zimmermann, HJ, Lewis, JH. Chemical and toxin-induced liver disease. Gastroenterol. Clin. N. Am. 1995; 24: 739.
59: Larrey, D.Hepatotoxicity of herbal remedies. J. Hepatol. 1997; 26: 47–54.
60: Eltumi, M, Trivedi, P, Hobbs, JR, Portman, B, Cheeseman, P, Downie, C et al. Monitoring of venoocclusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 1993; 342: 518–21.
61: Lassau, N, Leclére, J, Auperin, A, Bourhis, JH, Hartman, O, Valteau-Couanet, D et al. Hepatic veno-occlusive disease after myoablative treatment and bone marrow transplantation: value of Gray-scale and Doppler US in 100 patients. Radiology 1997; 204: 545–52.
62: Mowat, AP. Biliary disorders in childhood. Semin. Liver Dis. 1982; 2: 271–81.
63: Fried, MW, Connaghan, DG, Sharma, S, Martin, LG, Devine, S, Holland, K et al. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24: 588–91.
64: Norris, S, Crosbie, O, McEntee, G, Traynor, O, Molan, N, McCann, S et al. Orthotopic liver transplantation for veno-occlusive disease complicating autologous bone marrow transplantation. Ransplantation 1997; 63: 1521–4.
65: Huxtable, RJ. The myth of beneficient nature: the risks of herbal preparations. Ann. Int. Med. 1992; 117: 165–6.